Involvement of the heme oxygenase system in the development of preeclampsia and as a possible therapeutic target

Women's Health

Volumn 10, Issue 6, 2014, Pages 623-643

  Venditti, Carolina C ^a   Smith, Graeme N ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

carbon monoxide; heme oxygenase; preeclampsia; pregnancy; sFLT1; statin therapy

Indexed keywords

ATORVASTATIN; CARBON MONOXIDE; HEME OXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; MEVINOLIN; PLACENTAL GROWTH FACTOR; PRAVASTATIN; PROTEIN TYROSINE KINASE; ROSUVASTATIN; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL TONE; CARBON MONOXIDE INHALATION; CHORION VILLUS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM; ENDOTHELIUM INJURY; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; MATERNAL SMOKING; NONHUMAN; PLACENTA; PLACENTA DEVELOPMENT; PREECLAMPSIA; PREGNANCY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; SUPPLEMENTATION; ENZYMOLOGY; METABOLISM; PRE-ECLAMPSIA; SMOKING;

CARBON MONOXIDE; FEMALE; HEME OXYGENASE (DECYCLIZING); HUMANS; PRE-ECLAMPSIA; PREGNANCY; SMOKING;

EID: 84916641632     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.54     Document Type: Article

References (208)

1. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 46(6), 1243-1249 (2005).
2. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta 12(4), 301 (1991).
3. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2(10), 2557-2568 (1988).
4. Ryter SW, Otterbein LE, Morse D, Choi AMK. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional signifcance. Mol. Cell. Biochem. 234(1), 249-263 (2002).
5. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235(4792), 1043-1046 (1987).
6. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 99(10), 3505-3516 (2002).
7. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37(1), 517-554 (1997).
8. Zhao H, Wong RJ, Doyle TC et al. Regulation of maternal and fetal hemodynamics by heme oxygenase in mice. Biol. Reprod. 78(4), 744-751 (2008).
9. Acevedo CH, Ahmed A. Hemeoxygenase-1 inhibits human myometrial contractility via carbon monoxide and is upregulated by progesterone during pregnancy. J. Clin. Investig. 101(5), 949-955 (1998).
10. McLean M, Bowman M, Clifton V, Smith R, Grossman AB. Expression of the heme oxygenase-carbon monoxide signalling system in human placenta. J. Clin. Endocrinol. Metabol. 85(6), 2345-2349 (2000).
11. Yoshiki N, Kubota T, Aso T. Expression and localization of heme oxygenase in human placental villi. Biochem. Biophys. Res. Commun. 276 (3), 1136-1142 (2000).
12. Ahmed A, Rahman M, Zhang X et al. Induction of placental heme oxygenase-1 is protective against TNF-induced cytotoxicity and promotes vessel relaxation. Mol. Med. 6, 391-409 (2000).
13. Ihara N, Akagi R, Ejiri K, Kudo T, Furuyama K, Fujita H. Developmental changes of gene expression in heme metabolic enzymes in rat placenta. FEBS Lett. 439(1), 163-167 (1998).
14. Kreiser D, Kelly DK, Seidman DS, Stevenson DK, Baum M, Dennery P. Gestational pattern of heme oxygenase expression in the rat. Pediatr. Res. 54(2), 172-178 (2003).
15. Watanabe S, Akagi R, Mori M, Tsuchiya T, Sassa S. Marked developmental changes in heme oxygenase-1 (HO-1) expression in the mouse placenta: correlation between HO-1 expression and placental development. Placenta 25(5), 387-395 (2004).
16. McLaughlin BE, Lash GE, Smith GN et al. Heme oxygenase expression in selected regions of term human placenta. Exp. Biol. Med. (Maywood) 228(5), 564-567 (2003).
17. Bainbridge SA, Smith GN. HO in pregnancy. Free Radic. Biol. Med. 38(8), 979-988 (2005).
18. Levytska K, Baczyk D, Drewlo S. Heme oxygenase-1 in placental development and pathology. Placenta 34(4), 291-298 (2013).
19. George EM, Granger JP. Heme oxygenase in pregnancy and preeclampsia. Curr. Opin. Nephrol. Hypertens. 22(2), 156-162 (2013).
20. McLaughlin BE, Hutchinson JM, Graham CH et al. Heme oxygenase activity in term human placenta. Placenta 21(8), 870-873 (2000).
21. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase characterization of the enzyme. J. Biol. Chem. 244(23), 6388-6394 (1969).
22. Zenclussen AC, Lim E, Knoeller S et al. Heme oxygenases in pregnancy II. HO-2 is downregulated in human pathologic pregnancies. Am. J. Reprod. Immunol. 50(1), 66-76 (2003).
23. Farina A, Sekizawa A, De Sanctis P et al. Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenat. Diagn. 28 (10), 956-961 (2008).
24. Lash GE, McLaughlin BE, MacDonald-Goodfellow SK et al. Relationship between tissue damage and heme oxygenase expression in chorionic villi of term human placenta. Am. J. Physiol. Heart Circ. Physiol. 284 (1), H160-H167 (2003).
25. Nakamura M, Sekizawa A, Purwosunu Y et al. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat. Diagn. 29(7), 691-696 (2009).
26. Lyall F, Barber A, Myatt L, Bulmer JN, Robson SC. Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function. FASEB J. 14(1), 208-219 (2000).
27. Barber A, Robson SC, Myatt L, Bulmer JN, Lyall F. Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction. FASEB J. 15 (7), 1158-1168 (2001).
28. Zhao H, Azuma J, Kalish F, Wong RJ, Stevenson DK. Maternal heme oxygenase 1 regulates placental vasculature development via angiogenic factors in mice. Biol. Reprod. 85(5), 1005-1012 (2011).
29. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK. Effect of heme oxygenase-1 defciency on placental development. Placenta 30(10), 861-868 (2009).
30. Zenclussen ML, Casalis PA, El-Mousleh T et al. Haem oxygenase-1 dictates intrauterine fetal survival in mice via carbon monoxide. J. Pathol. 225(2), 293-304 (2011).
31. Yet SF, Perrella MA, Layne MD et al. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J. Clin. Investig. 103(8), R23-R29 (1999).
32. McCaig D, Lyall F. Inhibitors of heme oxygenase reduce invasion of human primary cytotrophoblast cells in vitro. Placenta 30(6), 536-538 (2009).
33. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl Acad. Sci. USA 94(20), 10919-10924 (1997).
34. Yachie A, Niida Y, Wada T et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 defciency. J. Clin. Investig. 103(1), 129-135 (1999).
35. American College of Obstetricians and Gynecologists, TaskForce on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 122 (5), 1122-1131 (2013).
36. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308(5728), 1592-1594 (2005).
37. Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 357(9249), 53-56 (2001).
38. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9(3), 147-160 (2002).
39. Tang LC, Kwok AC, Wong AY, Lee YY, Sun KO, So AP. Critical care in obstetrical patients: an eight-year review. Chin. Med. J. (Engl.) 110(12), 936-941 (1997).
40. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu. Rev. Pathol. Mech. Dis. 5, 173-192 (2010).
41. England L, Zhang J. Smoking and risk of preeclampsia: a systematic review. Front. Biosci. 12, 2471-2483 (2007).
42. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am. J. Obstetr. Gynecol. 181(4), 1026-1035 (1999).
43. Wikstrom AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk. Hypertension 55(5), 1254-1259 (2010).
44. Miller EC, Cao H, Wen SW, Yang Q, Lafeche J, Walker M. The risk of adverse pregnancy outcomes is increased in preeclamptic women who smoke compared with nonpreeclamptic women who do not smoke. Am. J. Obstetr. Gynecol. 203(4), 334.e1-8 (2010).
45. Lain KY, Wilson JW, Crombleholme WR, Ness RB, Roberts JM. Smoking during pregnancy is associated with alterations in markers of endothelial function. Am. J. Obstetr. Gynecol. 189(4), 1196-1201 (2003).
46. Zhang J, Klebanoff MA, Levine RJ, Puri M, Moyer P. The puzzling association between smoking and hypertension during pregnancy. Am. J. Obstetr. Gynecol. 181(6), 1407-1413 (1999).
47. Marcoux S, Brisson J, FABIA J. The effect of cigarette smoking on the risk of preeclampsia and gestational hypertension. Am. J. Epidemiol. 130(5), 950-957 (1989).
48. DiFranza JR, Lew RA. Effect of maternal cigarette smoking on pregnancy complications and sudden infant death syndrome. J. Fam. Pract. 40(4), 385-394 (1995).
49. Andres RL, Day MC. Perinatal complications associated with maternal tobacco use. Semin. Perinatol. 5 (3), 231-241 (2000).
50. Salihu HM, Wilson RE. Epidemiology of prenatal smoking and perinatal outcomes. Early Hum. Develop. 83(11), 713-720 (2007).
51. Millar WJ, Hill G. Pregnancy and smoking. Health Rep. 15 (4), 53-56 (2004).
52. Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmitters. Sci. Signal. 2(68), re2 (2009).
53. Ng SP, Zelikoff JT. Smoking during pregnancy: subsequent effects on offspring immune competence and disease vulnerability in later life. Reprod. Toxicol. 23(3), 428-437 (2007).
54. Persson PH, Grennert L, Gennser G, Kullander S. A study of smoking and pregnancy with special reference to fetal growth. Acta Obstet. Gynecol. Scand. 57, 33-39 (1978).
55. Naufal ZS, Marano KM, Kathman SJ, Wilson CL. Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999-2008. Biomarkers 16 (3), 222-235 (2011).
56. England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am. J. Obstetr. Gynecol. 189(4), 939-943 (2003).
57. Benowitz NL, Jacob III P. Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 35(4), 499-504 (1984).
58. Bhisey RA. Chemistry and toxicology of smokeless tobacco. Indian J. Cancer 49(4), 364-372 (2012).
59. Kreiser D, Baum M, Seidman DS et al. End tidal carbon monoxide levels are lower in women with gestational hypertension and pre-eclampsia. J. Perinatol. 24(4), 213-217 (2004).
60. Zhai D, Guo Y, Smith G, Krewski D, Walker M, Wen SW. Maternal exposure to moderate ambient carbon monoxide is associated with decreased risk of preeclampsia. Am. J. Obstet. Gynecol. 207(1), 57-59 (2012).
61. NATUS MEDICAL, INC: US6416479B1 (2002).
62. Savitz DA, Meyer RE, Tanzer JM, Mirvish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. Am. J. Public Health 96(11), 1934-1939 (2006).
63. Holm H, Jarvis MJ, Russell MA, Feyerabend C. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacol. (Berl.) 108(4), 507-511 (1992).
64. Russell MAH, Jarvis MJ, West RJ, Feyerabend C. Buccal absorption of nicotine from smokeless tobacco sachets. Lancet 326(8468), 1370 (1985).
65. Benowitz NL, Porchet H, Sheiner L, Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 44(1), 23-28 (1988).
66. Benowitz NL, Jacob P, Yu L. Daily use of smokeless tobacco: systemic effects. Ann. Intern. Med. 111 (2), 112-116 (1989).
67. Engel SM, Scher E, Wallenstein S et al. Maternal active and passive smoking and hypertensive disorders of pregnancy: risk with trimester-specifc exposures. Epidemiology 24(3), 379-386 (2013).
68. Yang Q, Wen SW, Smith GN et al. Maternal cigarette smoking and the risk of pregnancy-induced hypertension and eclampsia. Int. J. Epidemiol. 35(2), 288-293 (2006).
69. Roberts JM. Endothelial dysfunction in preeclampsia. Semin. Reprod. Med. 16, 5-15 (1998).
70. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Pre-eclampsia and fetal growth restriction: how morphometrically different is the placenta? Placenta 27(6-7), 727-734 (2006).
71. Coleman MAG, McCowan LME, North RA. Mid trimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high risk women. Ultrasound Obstet. Gynecol. 15(1), 7-12 (2000).
72. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ. Res. 90(12), 1274-1281 (2002).
73. Pijnenborg R, Robertson WB, Brosens I, Dixon G. Review article: trophoblast invasion and the establishment of haemochorial placentation in man and laboratory animals. Placenta 2(1), 71-91 (1981).
74. Knight M, Redman C W, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 105 (6), 632-640 (1998).
75. Goswami D, Tannetta DS, Magee LA et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 27(1), 56-61 (2006).
76. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoptosis in preeclampsia. Obstet. Gynecol. 96(2), 271 (2000).
77. Huppertz B. Apoptosis in the trophoblast-role of apoptosis in placental morphogenesis. J. Soc. Gynecol. Invest. 11(6), 353 (2004).
78. Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. Am. J. Obstet. Gynecol. 177(1), 57-65 (1997).
79. Marana HRC, Andrade JM, Martins GA, Silva JS, Sala MA, Cunha SP. A morphometric study of maternal smoking on apoptosis in the syncytiotrophoblast. Int. J. Gynecol. Obstet. 61(1), 21-27 (1998).
80. Gruslin A, Qiu Q, Tsang BK. Infuence of maternal smoking on trophoblast apoptosis throughout development: possible involvement of XIAP regulation. Biol. Reprod. 65 (4), 1164-1169 (2001).
81. Mehendale R, Hibbard J, Fazleabas A, Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am. J. Obstetr. Gynecol. 197(4), 363.e1-5 (2007).
82. Hosseini M. The effect of carbon monoxide solubility in water for biological removal process. (2012). www.ier-institute.org/2160-0589/abe6/V6/001.pdf
83. Bainbridge SA, Belkacemi L, Dickinson M, Graham CH, Smith GN. Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary necrosis in syncytiotrophoblast. Am. J. Pathol. 169(3), 774 (2006).
84. Sollwedel A, Bertoja AZ, Zenclussen ML et al. Protection from abortion by heme oxygenase-1 up-regulation is associated with increased levels of Bag-1 and neuropilin-1 at the fetal-maternal interface. J. Immunol. 175(8), 4875-4885 (2005).
85. Zenclussen ML, Anegon I, Bertoja AZ et al. Over-expression of heme oxygenase-1 by adenoviral gene transfer improves pregnancy outcome in a murine model of abortion. J. Reprod. Immunol. 69(1), 35-52 (2006).
86. George EM, Arany I. Induction of heme oxygenase-1 shifts the balance from proinjury to prosurvival in the placentas of pregnant rats with reduced uterine perfusion pressure. Am. J. Physiol. Regulat. Integr. Compar. Physiol. 302(5), R620-R626 (2012).
87. Brouard S, Otterbein LE, Anrather J et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J. Exp. Med. 192(7), 1015-1026 (2000).
88. Zhang X, Shan P, Alam J, Fu XY, Lee PJ. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J. Biol. Chem. 280(10), 8714 (2005).
89. World Health Organization: The Tobacco Atlas. (2004). www.tobaccoatlas.org/
90. Gunther L, Berberat PO, Haga M et al. Carbon monoxide protects pancreatic cells from apoptosis and improves islet function/survival after transplantation. Diabetes 51(4), 994 (2002).
91. Akamatsu Y, Haga M, Tyagi S et al. Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J. 18 (6), 771-772 (2004).
92. Zenclussen AC, Sollwedel A, Zambon Bertoja A et al. Heme oxygenase as a therapeutic target in immunological pregnancy complications. Int. Immunopharmacol. 5(1), 41-51 (2005).
93. Burton GJ, PALMER ME, Dalton J. Morphometric differences between the placental vasculature of non-smokers, smokers and ex-smokers. Br. J. Obstet. Gynaecol. 96(8), 907-915 (1989).
94. Jackson MR, Mayhew TM, Boyd PA. Quantitative description of the elaboration and maturation of villi from 10 weeks of gestation to term. Placenta 13(4), 357-370 (1992).
95. Pfarrer C, Macara L, Leiser R. Adaptive angiogenesis in placentas of heavy smokers. Lancet 354(9175), 303-303 (1999).
96. Howe DT, Wheeler T, Osmond C. The infuence of maternal haemoglobin and ferritin on mid-pregnancy placental volume. Br. J. Obstet. Gynaecol. 102 (3), 213-219 (1995).
97. Venditti CC, Casselman R, Murphy MS, Adamson SL, Sled JG, Smith GN. Chronic carbon monoxide inhalation during pregnancy augments uterine artery blood fow and uteroplacental vascular growth in mice. Am. J. Physiol. Regul. Integr. Compar. Physiol. 305(8), R939-R948 (2013).
98. Kadyrov N, Kosanke G. Increased fetoplacental angiogenesis during frst trimester in anaemic women. Lancet 352 (9142), 1747-1749 (1998).
99. Lindblad A, Marsal K, Andersson KE. Effect of nicotine on human fetal blood fow. Obstet. Gynecol. 72(3 Pt 1), 371-382 (1988).
100. Muller JS, Antunes M, Behle I, Teixeira L, Zielinsky P. Acute effects of maternal smoking on fetal-placental-maternal system hemodynamics. Arq. Bras. Cardiol. 78 (2), 152-155 (2002).
101. Lambers DS, Clark KE. The maternal and fetal physiologic effects of nicotine. Semin. Perinatol. 20(2), 115-126 (1996).
102. Bainbridge SA, Smith GN. The effect of nicotine on in vitro placental perfusion pressure. Canad. J. Physiol. Pharmacol. 84(8-9), 953-957 (2006).
103. Khosla S, Laddu A, Ehrenpreis S, Somberg JC. Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking. Am. Heart J. 127(6), 1669-1672 (1994).
104. Pastrakuljic A, Schwartz R, Simone C, Derewlany LO, Knie B, Koren G. Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. Life Sci. 63(26), 2333-2342 (1998).
105. Bainbridge SA, Farley AE, McLaughlin BE et al. Carbon monoxide decreases perfusion pressure in isolated human placenta. Placenta 23(8-9), 563-569 (2002).
106. Furchgott RF, Jothianandan D. Endothelium-dependent and-independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. J. Vasc. Res. 28(1-3), 52-61 (1991).
107. Ryan MJ, Jernigan NL, Drummond HA et al. Renal vascular responses to CORM-A1 in the mouse. Pharmacol. Res. 54(1), 24-29 (2006).
108. George EM, Hosick PA, Stec DE, Granger JP. Heme oxygenase inhibition increases blood pressure in pregnant rats. Am. J. Hypertens. 26(7), 924-930 (2013).
109. Botros T, Schwartzman ML, Stier T, Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int. 68(6), 2745-2755 (2005).
110. George EM, Cockrell K, Aranay M, Csongradi E, Stec DE, Granger JP. Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension 57(5), 941-948 (2011).
111. Zuckerbraun BS, Chin BY, Wegiel B et al. Carbon monoxide reverses established pulmonary hypertension. J. Exp. Med. 203(9), 2109-2119 (2006).
112. Johnson FK, Durante W, Peyton KJ, Johnson RA. Heme oxygenase inhibitor restores arteriolar nitric oxide function in Dahl rats. Hypertension 41(1), 149-155 (2003).
113. George EM, Arany M, Cockrell K, Storm MV, Stec DE, Granger JP. Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats. Am. J. Physiol. Regul. Integr. Compar. Physiol. 301(5), R1495-R1500 (2011).
114. Murphy SR, LaMarca BBD, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55(2), 394-398 (2010).
115. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50 (6), 1142-1147 (2007).
116. Muchova L, Wong RJ, Hsu M et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can. J. Physiol. Pharmacol. 85(8), 800-810 (2007).
117. Grosser N, Hemmerle A, Berndt G et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic. Biol. Med. 37(12), 2064-2071 (2004).
118. Costantine MM, Tamayo E, Lu F et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet. Gynecol. 116(1), 114-120 (2010).
119. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta 23(5), 359-372 (2002).
120. Hayman R, Brockelsby J, Kenny L, Baker P. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J. Soc. Gynecol. Investig. 6(1), 3-10 (1999).
121. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J. Clin. Investig. 52(11), 2682-2689 (1973).
122. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 285(12), 1607-1612 (2001).
123. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin. Obstet. Gynecol. 48(2), 372 (2005).
124. Spargo B, McCartney CP, Winemiller R. Glomerular capillary endotheliosis in toxemia of pregnancy. Arch. Pathol. 68, 593 (1959).
125. Blaauw J, Graaff R, van Pampus MG et al. Abnormal endothelium-dependent microvascular reactivity in recently preeclamptic women. Obstet. Gynecol. 105(3), 626-632 (2005).
126. Murphy MS, Casselman RC, Smith GN. Postpartum alterations in circulating endothelial progenitor cells in women with a history of pre-eclampsia. Pregnancy Hypertens. doi:10.1016/j.preghy.2013.03.004 (2013) (Epub ahead of print).
127. Sibai BM, Gordon T, Thom E et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Am. J. Obstetr. Gynecol. 172(2), 642-648 (1995).
128. Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-term prognosis of hypertension in pregnancy. Hypertens. Pregnancy 19(2), 199-209 (2000).
129. Sibai BM. Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J. Matern. Fetal Neonat. Med. 9(1), 62-65 (2000).
130. Ness RB, Markovic N, Bass D, Harger G, Roberts JM. Family history of hypertension, heart disease, and stroke among women who develop hypertension in pregnancy. Obstet. Gynecol. 102(6), 1366-1371 (2003).
131. Smith GN, Walker MC, Liu A et al. A history of preeclampsia identifes women who have underlying cardiovascular risk factors. Am. J. Obstetr. Gynecol. 200(1), 58 (2009).
132. Lyall F, Greer IA, Boswell F, Macara LM, Walker JJ. The cell adhesion molecule, VCAM 1, is selectively elevated in serum in pre eclampsia: does this indicate the mechanism of leucocyte activation? Br. J. Obstet. Gynaecol. 101(6), 485-487 (1994).
133. Krauss T, Kuhn W, Lakoma C, Augustin HG. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identifcation of pregnant women at risk for development of preeclampsia. Am. J. Obstetr. Gynecol. 177(2), 443-449 (1997).
134. Clark CJ, Boswell F, Greer IA, LYALL F. Treatment of endothelial cells with serum from women with preeclampsia: effect on neutrophil adhesion. J. Soc. Gynecol. Invest. 4(1), 27-33 (1997).
135. Harlan JM. Neutrophil mediated vascular injury. Acta Med. Scand. 221(S715), 123-129 (1987).
136. Song H, Bergstrasser C, Rafat N et al. The carbon monoxide releasing molecule (CORM-3) inhibits expression of vascular cell adhesion molecule-1 and E-selectin independently of haem oxygenase-1 expression. Br. J. Pharmacol. 157 (5), 769-780 (2009).
137. Zhang H, Zheng F, Zhao J, Guo D, Chen X. Genistein inhibits ox-LDL-induced VCAM-1, ICAM-1 and MCP-1 Expression of HUVECs through heme oxygenase-1. Arch. Med. Res. 44(1), 13-20 (2013).
138. Bergstraesser C, Hoeger S, Song H et al. Inhibition of VCAM-1 expression in endothelial cells by CORM-3: the role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. Free Radic. Biol. Med. 52(4), 794-802 (2012).
139. Bainbridge SA, Sidle EH, Smith GN. Direct placental effects of cigarette smoke protect women from pre-eclampsia: the specifc roles of carbon monoxide and antioxidant systems in the placenta. Med. Hypotheses 64(1), 17-27 (2005).
140. Otterbein LE, Bach FH, Alam J et al. Carbon monoxide has anti-infammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6(4), 422-428 (2000).
141. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symposia Soc. Exp. Biol. 7, 320-338 (1953).
142. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
143. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5(3), 266-271 (2004).
144. + T regulatory cells prevents fetal rejection in a murine abortion model. Am. J. Pathol. 166(3), 811-822 (2005).
145. + regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol. Hum. Reprod. 10(5), 347-353 (2004).
146. Zenclussen AC, Gerlof K, Zenclussen ML et al. Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur. J. Immunol. 36(1), 82-94 (2006).
147. Schumacher A, Wafula PO, Teles A et al. Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells. PLoS ONE 7(8), e42301 (2012).
148. Lee TS, Chang CC, Zhu Y, Shyy JYJ. Simvastatin induces heme oxygenase-1 A novel mechanism of vessel protection. Circulation 110 (10), 1296-1302 (2004).
149. Yamashita K, Ollinger R, McDaid J et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J. 20(6), 776-778 (2006).
150. Soares MP, Lin Y, Anrather J et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat. Med. 4(9), 1073-1077 (1998).
151. Bach FH, Ferran C, Hechenleitner P et al. Accommodation of vascularized xenografts: expression of 'protective genes' by donor endothelial cells in a host Th2 cytokine environment. Nat. Med. 3 (2), 196-204 (1997).
152. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 270(5236), 630-633 (1995).
153. Katori M, Busuttil RW, Kupiec-Weglinski JW. Heme oxygenase-1 system in organ transplantation. Transplantation 74(7), 905-912 (2002).
154. Sidle EH, Casselman R, Smith GN. Effect of cigarette smoke on placental antioxidant enzyme expression. Am. J. Physiol. Regul. Integr. Compar. Physiol. 293(2), R754-R758 (2007).
155. Torry DS, Torry RJ. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am. J. Reprod. Immunol. 37(1), 21-29 (1997).
156. Zhou Y, McMaster M, Woo K et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160(4), 1405 (2002).
157. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Investig. 111(5), 649-658 (2003).
158. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672-683 (2004).
159. Kendall RL, Wang G, Thomas KA. Identifcation of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226(2), 324-328 (1996).
160. Koga K, Osuga Y, Yoshino O et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metabol. 88(5), 2348-2351 (2003).
161. Powers RW, Roberts JM, Cooper KM et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am. J. Obstetr. Gynecol. 193(1), 185-191 (2005).
162. Li Z, Zhang Y, Ying Ma J et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50(4), 686-692 (2007).
163. Lu F, Longo M, Tamayo E et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstetr. Gynecol. 196 (4), 396.e1-7(2007).
164. Bergmann A, Ahmad S, Cudmore M et al. Reduction of circulating soluble Flt 1 alleviates preeclampsia like symptoms in a mouse model. J. Cell. Mol. Med. 14(6b), 1857-1867 (2010).
165. Mateus J, Bytautiene E, Lu F et al. Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1. Am. J. Physiol. Heart Circ. Physiol. 301(5), H1781-H1787 (2011).
166. Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem. Soc. Transact. 37(Pt 6), 1237-1242 (2009).
167. Thadhani R, Kisner T, Hagmann H et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124(8), 940-950 (2011).
168. Cudmore M, Ahmad S, Al-Ani B et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115 (13), 1789-1797 (2007).
169. Jeyabalan A, Powers RW, Durica AR, Harger G, Roberts JM, Ness RB. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am. J. Hypertens. 21(8), 943 (2008).
170. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355(10), 992-1005 (2006).
171. Belgore FM, Lip GY, Blann AD. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br. J. Biomed. Sci. 57(3), 207 (2000).
172. George EM, Colson D, Dixon J, Palei AC, Granger JP. Heme oxygenase-1 attenuates hypoxia-induced sFlt-1 and oxidative stress in placental villi through its metabolic products CO and bilirubin. Int. J. Hypertens. doi:10.1155/2012/486053 (2011) (Epub ahead of print).
173. Dulak J, Jozkowicz A, Foresti R et al. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid. Redox Signal. 4(2), 229-240 (2002).
174. Walshe TE, Dole VS, Maharaj ASR, Patten IS, Wagner DD, D'Amore PA. Inhibition of VEGF or TGF-á signaling activates endothelium and increases leukocyte rolling. Arterioscler. Thromb. Vasc. Biol. 29 (8), 1185-1192 (2009).
175. Sato K, Balla J, Otterbein L et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J. Immunology 166 (6), 4185-4194 (2001).
176. Von Burg R. Carbon monoxide. J. Appl. Toxicol. 19 (5), 379-386 (1999).
177. Bauer I, Pannen BH. Bench-to-bedside review: carbon monoxide-from mitochondrial poisoning to therapeutic use. Crit. Care 13(4), 220 (2009).
178. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57(4), 585-630 (2005).
179. Vreman HJ, Kwong LK, Stevenson DK. Carbon monoxide in blood: an improved microliter blood-sample collection system, with rapid analysis by gas chromatography. Clin. Chem. 30(8), 1382-1386 (1984).
180. Osborne JS, Adamek S, Hobbs ME. Some components of gas phase of cigarette smoke. Anal. Chem. 28(2), 211-215 (1956).
181. Haddad LM, Winchester JF. Clinical Management Of Poisoning And Drug Overdose. WB Saunders Company, Philadelphia, USA (1983).
182. Longo LD. Carbon monoxide in the pregnanct mother and fetus and its exchange across the placenta. Ann. N. Y. Acad. Sci. 174(1), 313-341 (1970).
183. Longo LD, Hill EP. Carbon monoxide uptake and elimination in fetal and maternal sheep. Am. J. Physiol. Heart Circ. Physiol. 232(3), H324-H330 (1977).
184. Baum M, Schiff E, Kreiser D et al. End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. Am. J. Obstetr. Gynecol. 183(4), 900-903 (2000).
185. Ahmed A. New insights into the etiology of preeclampsia: identifcation of key elusive factors for the vascular complications. Thromb. Res. 127(Suppl. 3), S72-S75 (2011).
186. Venditti CC, Casselman R, Smith GN. Effects of chronic carbon monoxide exposure on fetal growth and development in mice. BMC Pregnancy Childbirth 11(1), 101 (2011).
187. Mayr FB, Spiel A, Leitner J et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am. J. Respir. Crit. Care Med. 171(4), 354-360 (2005).
188. Bathoorn E, Slebos DJ, Postma DS et al. Anti-infammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur. Respir. J. 30 (6), 1131-1137 (2007).
189. El-Mousleh T, Casalis PA, Wollenberg I et al. Exploring the potential of low doses carbon monoxide as therapy in pregnancy complications. Med. Gas Res. 2(1), 4 (2012).
190. Li C, Hossieny P, Wu BJ, Qawasmeh A, Beck K, Stocker R. Pharmacologic induction of heme oxygenase-1. Antioxid. Redox Signal. 9(12), 2227-2240 (2007).
191. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 101(2), 207-213 (2000).
192. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282(24), 2340-2346 (1999).
193. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11), 1712-1719 (2001).
194. Vitek L, Lenicek M. Cytoprotective and antiproliferative effects of HMG-CoA reductase inhibitors. Curr. Enzyme Inhibit. 2(3), 261-280 (2006).
195. Dulak J, Loboda A, Jazwa A et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium 12(5-6), 233-241 (2005).
196. Grosser N, Erdmann K, Hemmerle A et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem. Biophys. Res. Commun. 325(3), 871-876 (2004).
197. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 28(3), 449-456 (1983).
198. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Research Part A. Clin. Mol. Teratol. 73(11), 888-896 (2005).
199. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol. 10(6), 439-446 (1996).
200. Taguchi N, Rubin ET, Hosokawa A et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 26(2), 175-177 (2008).
201. Hosokawa A, Bar-Oz B, Ito S. Use of lipid-lowering agents (statins) during pregnancy. Can. Family Phys. 49 (6), 747-749 (2003).
202. Morton S, Thangaratinam S. Statins in pregnancy. Curr. Opin. Obstet. Gynecol. 25(6), 433-440 (2013).
203. Kumasawa K, Ikawa M, Kidoya H et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc. Natl Acad. Sci. USA 108(4), 1451-1455 (2011).
204. Fox KA, Longo M, Tamayo E et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am. J. Obstetr. Gynecol. 205(4), 366.e1-5 (2011).
205. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 58(4), 716-724 (2011).
206. Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet. Gynecol. 121(2 Pt 1), 349-353 (2013).
207. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Pravastatin for the prevention of preeclampsia (2014). http://clinicaltrials.gov/show/NCT01717586
208. Medical Research Council. The StAmP trial: a proof of principle, double-blind, randomised placebo-controlled multicentre trial of pravaStatin to Ameliorate early-onset Preeclampsia (2014). http://clinicaltrials.gov/show/NCT01717586